Журналов:     Статей:        

Инфекция и иммунитет. 2015; 5: 143-147

КЛИНИКО-ЛАБОРАТОРНАЯ ОЦЕНКА ЭФФЕКТИВНОСТИ ПРИМЕНЕНИЯ ОЗЕЛЬТАМИВИРА ДЛЯ ЛЕЧЕНИЯ ГРИППА У ГОСПИТАЛИЗИРОВАННЫХ ПАЦИЕНТОВ

Волощук Любовь Васильевна, Головачева Е. Г., Го А. А., Мушкатина А. Л., Заришнюк П. В., Днепровская Г. Л., Тумина Т. Л.

https://doi.org/10.15789/2220-7619-2015-2-143-147

Аннотация

Целью настоящего исследования являлось изучение эффективности противовирусного препарата Озельтамивир в лечении гриппа. Оценивалось влияние Озельтамивира на клиническую картину и иммунный статус у 75 госпитализированных пациентов. Было сформировано 2 группы наблюдения с подтвержденным диагнозом «грипп»: 38 человек, получавших терапию Озельтамивиром, и 37 человек, получавших патогенетическое лечение. Показано, что лечение Озельтамивиром способствует достоверному сокращению длительности катарального и интоксикационного синдромов, а также предотвращает развитие у пациентов осложнений и обострений хронических инфекций, что говорит о его высокой противовирусной активности. Оценивая динамику показателей IL-1β, IL-8, IFNα, IFNγ в сыворотке крови можно предположить о положительном влиянии Озельтамивира на восстановление нарушенного баланса цитокинов.
Список литературы

1. Беляева Т.В., Исаков В.А., Рахманова А.Г., Тимченко В.И., Каболова И.В., Яковлев А.А. Грипп А (Н1N1) Калифорния («свиной грипп»). Клиника, диагностика, этиология: Методические рекомендации для врачей. СПб., 2009. 87 с. [Belyaeva T.V., Isakov V.A., Rakhmanova A.G., Timchenko V.I., Kabolova I.V., Yakovlev A.A. Gripp A (N1N1) Kaliforniya («svinoi gripp»). Klinika, diagnostika, etiologiya: Metodicheskie rekomendatsii dlya vrachei [Influenza A (H1N1) California («swine flu»). Clinic, diagnosis, etiology: Methodical recommendations for doctors]. St. Petersburg, 2009, 87 p.]

2. Еженедельный бюллетень по информированному мониторингу проявлений гриппа H1N1 и других генотипов вируса с пандемическим потенциалом за период 09.05.2010–16.06.2010 // Референс-лаборатория ВОЗ по диагностике гриппа Н5 ФГУН ГНЦВБ. Выпуск 7. 25 с. [Ezhenedel’nyi byulleten’ po informirovannomu monitoringu proyavlenii grippa H1N1 i drugikh genotipov virusa s pandemicheskim potentsialom za period 09.05.2010–16.06.2010 [Weekly Bulletin informed monitoring of manifestations of H1N1 and other strains of the virus with pandemic potential during the period 09.05.2010–16.06.2010]. Referens-laboratoriya VOZ po diagnostike grippa H5 FGUN GNTsVB = Reference Laboratory WHO for the Diagnosis of Influenza H5 FSRI GMCVB, iss. 7, 25 p. (In Russ.)]

3. Инфекционная заболеваемость за январь–декабрь 2008 г. в Российской Федерации // Детские инфекции. 2009. Т. 8. С. 1–3. [Infektsionnaya zabolevaemost’ za yanvar’–dekabr’ 2008 g. v Rossiiskoi Federatsii [Infectious morbidity in January–December of 2008 in the Russian Federation] Detskie infektsii = Childhood infections. 2009, vol. 8, pp. 1–3. (In Russ.)]

4. Сведения об инфекционных и паразитарных заболеваниях за январь–декабрь 2010. Российская Федерация // Детские инфекции. 2011. Т. 10. № 2. С. 3. [Information about infectious and parasitic diseases, January–December 2010. Russian Federation. Detskie infektsii = Childhood infections, 2011, vol. 10, no. 2, p. 3. (In Russ.)]

5. Яковлев А.А., Полушин Ю.С., Котлярова С.И., Мусатов В.Б., Федуняк И.П., Цинзерлинг В.А., Вашукова С.С., Лукашевич Э.Н. Грипп A Н1N1/2009 Калифорния — reassortment of vRNAs — как медицинская проблема // Вестник Санкт-Петербургского университета. 2010. № 3. С. 45–55. [Yakovlev A.A., Polushin Y.S., Kotlyarova S.I., Musatov V.B., Feduniak I.P., Zinserling V.A., Vashukova S.S., Lukashevich E.N. Influenza A H1N1/2009 California reassortment of vRNAs as a medical problem. Vestnik Sankt-Peterburgskogo universiteta = Herald of St. Petersburg University, 2010, no. 3, pp. 45–55. (In Russ.)]

6. Bussfeld D., Bacher M., Moritz A., Gemsa D., Sprenger H. Expression of transcription factor genes after influenza virus A infection. Immunobiology, 1997, vol. 198, pp. 291–298. doi: 10.1016/S0171-2985(97)80049-6

7. CDC news conference with Thomas R. Frieden. Centers for Disease Control and Prevention, Dec. 10, 2009.

8. McPhie K., Taylor J., Rashid H., Heron L., Dwyer D., Booy R. A randomized study of standard Dixit R., Khandaker G., Hay P., versus double dose oseltamivir for treating influenza in the community. Antivir. Ther., 2014, 10 p. doi: 10.3851/IMP2807

9. Hermes-Lima M., Storey J.M., Storey K.B. Antioxidant defenses and metabolic depression. The hypothesis of preparation for oxidative stress in land snails. Comp. Biochem. Physiol. B. Biochem. Mol. Biol., 1998, vol. 120, pp. 437–448. doi: 10.1016/S0305-0491(98)10053-6

10. Garg S., Fry A.M., Patton M., Fiore A.E., Finelli L. Antiviral treatment of influenza in children. Pediatr. Infect. Dis. J., 2012, vol. 31, iss. 2, pp. 43–51. doi: 10.1097/INF.0b013e31824671ab

11. Louie J.K., Schechter R., Honarmand S., Guevara H.F., Shoemaker T.R., Madrigal N.Y., Woodfill C.J., Backer H.D., Glaser C.A. Severe pediatric influenza in California, 2003–2005: implications for immunization recommendation. J. Pediatr., 2006, vol. 117, pp. 610–618. doi: 10.1542/peds.2005-1373

12. Nguyen H.T., Fry A.M., Gubareva L.V. Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods. Antivir. Ther., 2012, vol. 17, no. 1, pp. 159–173. doi: 10.3851/IMP2067

13. -Pascual L., Arjona-Berral J.E., Mar Nieto ín-Martín E.M., Muñoz-Gomariz E., Ilich I., Castelo-Branco C. Early prophylactic treatment in pregnant women during the 2009–2010 H1N1 pandemic: obstetric and neonatal outcomes. J. Obstet. Gynaecol., 2013, vol. 33, no. 2, pp. 128–134. doi: 10.3109/01443615.2012.740526

14. Ramshaw I.A., Ramsay A.J., Karupiah G., Rolph M.S., Mahalingam S., Ruby J.C. Cytokines and immunity to viral infections. Immunol. Rev., 1998, vol. 159, no. 1, pp. 69–77. doi: 10.1111/j.1600-065X.1997.tb01011.x

15. Wong Z.X., Jones J.E., Anderson G.P., Gualano R.C. Oseltamivir treatment of mice before or after mild influenza infection reduced cellular and cytokine inflammation in the lung. Influenza Other Respir. Viruses, 2011, vol. 5, iss. 5, pp. 343–350. doi: 10.1111/j.1750-2659.2011.00235.x

Russian Journal of Infection and Immunity. 2015; 5: 143-147

THE CLINICAL AND LABORATORY EFFECTIVENESS OF OSELTAMIVIR FOR TREATMENT OF INFLUENZA IN HOSPITALIZED PATIENTS

Voloschcuk L. V., Golovacheva E. G., Go A. A., Mushkatina A. L., Zarishnuk P. V., Dnieprovskay G. L., Tumina T. L.

https://doi.org/10.15789/2220-7619-2015-2-143-147

Abstract

The goal of our study was to estimate the efficacy of antiviral drug Oseltamivir for influenza treatment. We assessed the effect of Oseltamivir on the immune status of the 75 patients. It was formed 2 groups of observations with confirmed diagnosis of influenza: 38 received therapy Oseltamivir and 37 people receiving pathogenetic treatment. Treatment Oseltamivir contributes to a significant reduction in the duration of the catarrhal and intoxication syndromes and prevents the development of complications and exacerbations of chronic disease in persons with modified backdrop premorbid, which indicates for its high antiviral activity. We can assume the effect of Oseltamivir for restore the disturbed balance of cytokines, on assessing the dynamics of IL-1β, IL-8, IFNα, IFNγ in the serum.
References

1. Belyaeva T.V., Isakov V.A., Rakhmanova A.G., Timchenko V.I., Kabolova I.V., Yakovlev A.A. Gripp A (N1N1) Kaliforniya («svinoi gripp»). Klinika, diagnostika, etiologiya: Metodicheskie rekomendatsii dlya vrachei. SPb., 2009. 87 s. [Belyaeva T.V., Isakov V.A., Rakhmanova A.G., Timchenko V.I., Kabolova I.V., Yakovlev A.A. Gripp A (N1N1) Kaliforniya («svinoi gripp»). Klinika, diagnostika, etiologiya: Metodicheskie rekomendatsii dlya vrachei [Influenza A (H1N1) California («swine flu»). Clinic, diagnosis, etiology: Methodical recommendations for doctors]. St. Petersburg, 2009, 87 p.]

2. Ezhenedel'nyi byulleten' po informirovannomu monitoringu proyavlenii grippa H1N1 i drugikh genotipov virusa s pandemicheskim potentsialom za period 09.05.2010–16.06.2010 // Referens-laboratoriya VOZ po diagnostike grippa N5 FGUN GNTsVB. Vypusk 7. 25 s. [Ezhenedel’nyi byulleten’ po informirovannomu monitoringu proyavlenii grippa H1N1 i drugikh genotipov virusa s pandemicheskim potentsialom za period 09.05.2010–16.06.2010 [Weekly Bulletin informed monitoring of manifestations of H1N1 and other strains of the virus with pandemic potential during the period 09.05.2010–16.06.2010]. Referens-laboratoriya VOZ po diagnostike grippa H5 FGUN GNTsVB = Reference Laboratory WHO for the Diagnosis of Influenza H5 FSRI GMCVB, iss. 7, 25 p. (In Russ.)]

3. Infektsionnaya zabolevaemost' za yanvar'–dekabr' 2008 g. v Rossiiskoi Federatsii // Detskie infektsii. 2009. T. 8. S. 1–3. [Infektsionnaya zabolevaemost’ za yanvar’–dekabr’ 2008 g. v Rossiiskoi Federatsii [Infectious morbidity in January–December of 2008 in the Russian Federation] Detskie infektsii = Childhood infections. 2009, vol. 8, pp. 1–3. (In Russ.)]

4. Svedeniya ob infektsionnykh i parazitarnykh zabolevaniyakh za yanvar'–dekabr' 2010. Rossiiskaya Federatsiya // Detskie infektsii. 2011. T. 10. № 2. S. 3. [Information about infectious and parasitic diseases, January–December 2010. Russian Federation. Detskie infektsii = Childhood infections, 2011, vol. 10, no. 2, p. 3. (In Russ.)]

5. Yakovlev A.A., Polushin Yu.S., Kotlyarova S.I., Musatov V.B., Fedunyak I.P., Tsinzerling V.A., Vashukova S.S., Lukashevich E.N. Gripp A N1N1/2009 Kaliforniya — reassortment of vRNAs — kak meditsinskaya problema // Vestnik Sankt-Peterburgskogo universiteta. 2010. № 3. S. 45–55. [Yakovlev A.A., Polushin Y.S., Kotlyarova S.I., Musatov V.B., Feduniak I.P., Zinserling V.A., Vashukova S.S., Lukashevich E.N. Influenza A H1N1/2009 California reassortment of vRNAs as a medical problem. Vestnik Sankt-Peterburgskogo universiteta = Herald of St. Petersburg University, 2010, no. 3, pp. 45–55. (In Russ.)]

6. Bussfeld D., Bacher M., Moritz A., Gemsa D., Sprenger H. Expression of transcription factor genes after influenza virus A infection. Immunobiology, 1997, vol. 198, pp. 291–298. doi: 10.1016/S0171-2985(97)80049-6

7. CDC news conference with Thomas R. Frieden. Centers for Disease Control and Prevention, Dec. 10, 2009.

8. McPhie K., Taylor J., Rashid H., Heron L., Dwyer D., Booy R. A randomized study of standard Dixit R., Khandaker G., Hay P., versus double dose oseltamivir for treating influenza in the community. Antivir. Ther., 2014, 10 p. doi: 10.3851/IMP2807

9. Hermes-Lima M., Storey J.M., Storey K.B. Antioxidant defenses and metabolic depression. The hypothesis of preparation for oxidative stress in land snails. Comp. Biochem. Physiol. B. Biochem. Mol. Biol., 1998, vol. 120, pp. 437–448. doi: 10.1016/S0305-0491(98)10053-6

10. Garg S., Fry A.M., Patton M., Fiore A.E., Finelli L. Antiviral treatment of influenza in children. Pediatr. Infect. Dis. J., 2012, vol. 31, iss. 2, pp. 43–51. doi: 10.1097/INF.0b013e31824671ab

11. Louie J.K., Schechter R., Honarmand S., Guevara H.F., Shoemaker T.R., Madrigal N.Y., Woodfill C.J., Backer H.D., Glaser C.A. Severe pediatric influenza in California, 2003–2005: implications for immunization recommendation. J. Pediatr., 2006, vol. 117, pp. 610–618. doi: 10.1542/peds.2005-1373

12. Nguyen H.T., Fry A.M., Gubareva L.V. Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods. Antivir. Ther., 2012, vol. 17, no. 1, pp. 159–173. doi: 10.3851/IMP2067

13. -Pascual L., Arjona-Berral J.E., Mar Nieto ín-Martín E.M., Muñoz-Gomariz E., Ilich I., Castelo-Branco C. Early prophylactic treatment in pregnant women during the 2009–2010 H1N1 pandemic: obstetric and neonatal outcomes. J. Obstet. Gynaecol., 2013, vol. 33, no. 2, pp. 128–134. doi: 10.3109/01443615.2012.740526

14. Ramshaw I.A., Ramsay A.J., Karupiah G., Rolph M.S., Mahalingam S., Ruby J.C. Cytokines and immunity to viral infections. Immunol. Rev., 1998, vol. 159, no. 1, pp. 69–77. doi: 10.1111/j.1600-065X.1997.tb01011.x

15. Wong Z.X., Jones J.E., Anderson G.P., Gualano R.C. Oseltamivir treatment of mice before or after mild influenza infection reduced cellular and cytokine inflammation in the lung. Influenza Other Respir. Viruses, 2011, vol. 5, iss. 5, pp. 343–350. doi: 10.1111/j.1750-2659.2011.00235.x